Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (101-110 of 238) with videos related to

Pageof 24
Sort By:
The Journal of Biological Chemistry|November 20, 1997
Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivoP E Scherer, R Y Lewis, D Volonte, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2016
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression BiopsiesMeghan Campo, David Gerber, Justin F Gainor, et al.
Cancer Research|May 21, 2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancerJer-Yen Yang, Chun-Ju Chang, Weiya Xia, et al.
The Journal of Biological Chemistry|August 1, 1998
Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancerJ A Engelman, R J Lee, A Karnezis, et al.
British Journal of Cancer|September 3, 2010
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancerY Baba, K Nosho, K Shima, et al.
Molecular and Cellular Biology|March 9, 2002
Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolaeBabak Razani, Xiao Bo Wang, Jeffery A Engelman, et al.
Annals of Nuclear Medicine|April 23, 2015
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot studyEliot T McKinley, Jennifer M Watchmaker, A Bapsi Chakravarthy, et al.
The Journal of Clinical Investigation|June 24, 2008
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsMarta Guix, Anthony C Faber, Shizhen Emily Wang, et al.
Molecular Cancer Research : MCR|March 12, 2021
RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell ProliferationMatthew S Crowe, Tatiana Zavorotinskaya, Charles F Voliva, et al.
Pageof 24

Showing results (101-110 of 238) with videos related to

Sort By:
Pageof 24
The Journal of Biological Chemistry|November 20, 1997
Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivoP E Scherer, R Y Lewis, D Volonte, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 20, 2011
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKRyohei Katayama, Tahsin M Khan, Cyril Benes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2016
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression BiopsiesMeghan Campo, David Gerber, Justin F Gainor, et al.
Cancer Research|May 21, 2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancerJer-Yen Yang, Chun-Ju Chang, Weiya Xia, et al.
The Journal of Biological Chemistry|August 1, 1998
Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancerJ A Engelman, R J Lee, A Karnezis, et al.
British Journal of Cancer|September 3, 2010
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancerY Baba, K Nosho, K Shima, et al.
Molecular and Cellular Biology|March 9, 2002
Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolaeBabak Razani, Xiao Bo Wang, Jeffery A Engelman, et al.
Annals of Nuclear Medicine|April 23, 2015
[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot studyEliot T McKinley, Jennifer M Watchmaker, A Bapsi Chakravarthy, et al.
The Journal of Clinical Investigation|June 24, 2008
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsMarta Guix, Anthony C Faber, Shizhen Emily Wang, et al.
Molecular Cancer Research : MCR|March 12, 2021
RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell ProliferationMatthew S Crowe, Tatiana Zavorotinskaya, Charles F Voliva, et al.
Pageof 24